Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray

The week saw FDA reprimanding a pharma giant for making false and misleading claims about its non-small cell lung cancer drug and a developer of MDMA therapy for PTSD facing a major setback. On the drug development front, acute myeloid leukemia drug candidate Iomab-B faced a significant setback while a DMD drug candidate produced exciting data in a study.

from RTT - Top Story https://ift.tt/gesh87A
via IFTTT